| Gene symbol | APOA1 | Synonyms | AMYLD3, HPALP2, apo(a) | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | apolipoprotein A1 | ||||
| GTO ID | GTC0208 |
| Trial ID | NCT02160899 |
| Disease | Elevated Lipoprotein |
| Altered gene | APOA1 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS 494372|ISIS-APO(a)Rx |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a) |
| Year | 2014 |
| Country | Canada|Denmark|Germany|Netherlands|United Kingdom |
| Company sponsor | Ionis Pharmaceuticals, Inc. |
| Other ID(s) | ISIS 494372-CS3|2014-000701-13 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||